ADAM10 and cancer: Specifically, ADAM10 regulates constitutive LAG3 cleavage, while ADAM17 regulates LAG3 cleavage induced by T cell receptor signaling (44), where ADAM17 showed immune and SARS-CoV-2 entry for the expression in patients with cancer (49).